-
CURC & ARUF | Professor Tao Xu: New Perspectives on Endocrine Therapy for mHSPC — Evidence Review and Clinical Practice Centered on Enzalutamide
Prostate cancer is one of the most common malignant tumors of the male genitourinary system in China. Among these patients, metastatic hormone-sensitive prostate cancer (mHSPC) carries a particularly poor prognosis and remains a major clinical challenge. In recent years, novel hormonal therapies (NHTs), represented by enzalutamide, have continuously reshaped the treatment landscape of mHSPC. With…
-
4th Clinical Research Conference on Urologic Oncology | Breaking Through the Post-PD-1 Era: Professor Xieqiao Yan Interprets the Latest Advances in Kidney Cancer Research from ASCO GU 2026
At the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Professor Xieqiao Yan from Peking University Cancer Hospital delivered a comprehensive presentation on the latest advances in kidney cancer therapy. His report focused on emerging clinical evidence surrounding the HIF-2α inhibitor belzutifan, particularly its evolving role in advanced clear cell renal cell…
-
2nd Peking University Urology Academic Forum | Professor Jianye Wang: Current Priorities, Clinical Challenges, and Future Directions in Urinary Continence and Pelvic Floor Disorders
Urinary continence and pelvic floor disorders represent an important subspecialty within urology. Conditions such as post-prostatectomy urinary incontinence and overactive bladder (OAB), which are particularly common in elderly populations, can severely compromise patients’ quality of life.
-
2nd Peking University Urology Academic Forum | Professor Xuesong Li: Innovation and Leadership in Integrated Management of Benign and Malignant Upper Urinary Tract Diseases
The 2nd Peking University Urology Academic Forum focused on the integrated and collaborative management of benign and malignant diseases of the upper urinary tract. As conference chair, Professor Xuesong Li from the Department of Urology at Peking University First Hospital shared his team’s long-standing experience and insights into the field’s major clinical challenges, key innovations,…
-
2nd Peking University Urology Academic Forum | Professor Chaohui Gu: Umbilical Artery Ligament Suspension—A New Breakthrough for Immediate Urinary Continence After Radical Prostatectomy
At the 2nd Peking University Urology Academic Forum and the 80th Anniversary Celebration of the Department of Urology at Peking University First Hospital, Oncology Frontier – UroStream interviewed Professor Chaohui Gu from the Department of Urology, The First Affiliated Hospital of Zhengzhou University.
-
2nd Peking University Urology Academic Forum | Professor Wei Zhu: FANS Technology Revolutionizes Flexible Ureteroscopic Lithotripsy Through Clinician–Engineer Innovation
Flexible ureteroscopic lithotripsy is an important treatment modality for upper urinary tract stones. However, conventional procedures are associated with several limitations, including low stone-free rates, elevated intrarenal pressure during surgery, and increased risks of postoperative infection and ureteral stricture.
-
International Perspectives from EBMT | Professor Florent Malard: New Frontiers in Microbiome-Based Therapy for the Treatment and Prevention of Graft-versus-Host Disease
Graft-versus-host disease (GVHD) remains one of the most severe complications following hematopoietic stem cell transplantation. Among its manifestations, acute gastrointestinal GVHD is particularly challenging to manage. Despite standard therapies, a substantial proportion of patients fail treatment, and no approved therapeutic options currently exist for those with refractory disease, representing a major unmet medical need.
-
Professor Liqun Zou: Advances in the Diagnosis and Treatment of Peripheral T-Cell Lymphoma | 2026 CACA Western Integrated Oncology Conference
Amid the vibrant renewal of spring, the 2026 CACA Western Integrated Oncology Conference was grandly convened in Chengdu, Sichuan. The meeting brought together leading oncology experts from across China to explore the frontiers of precision oncology and advance integrated, whole-course cancer care.
Connecting Medical Expertise through Media